GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » Cyclically Adjusted Price-to-FCF

Novartis AG (Novartis AG) Cyclically Adjusted Price-to-FCF : 18.57 (As of Apr. 28, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Novartis AG Cyclically Adjusted Price-to-FCF?

As of today (2024-04-28), Novartis AG's current share price is $96.00. Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $5.17. Novartis AG's Cyclically Adjusted Price-to-FCF for today is 18.57.

The historical rank and industry rank for Novartis AG's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

NVSEF' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 14.52   Med: 17.76   Max: 21.84
Current: 19.11

During the past years, Novartis AG's highest Cyclically Adjusted Price-to-FCF was 21.84. The lowest was 14.52. And the median was 17.76.

NVSEF's Cyclically Adjusted Price-to-FCF is ranked better than
69.54% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.81 vs NVSEF: 19.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novartis AG's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.539. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $5.17 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Price-to-FCF Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.49 19.15 17.79 17.74 18.20

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.27 18.32 18.84 18.20 18.65

Competitive Comparison of Novartis AG's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.



Novartis AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novartis AG's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=96.00/5.17
=18.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.539/106.4611*106.4611
=0.539

Current CPI (Mar. 2024) = 106.4611.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.963 101.517 1.010
201409 1.224 101.247 1.287
201412 1.778 100.704 1.880
201503 0.404 100.339 0.429
201506 0.762 100.464 0.807
201509 0.962 99.785 1.026
201512 1.318 99.386 1.412
201603 0.347 99.475 0.371
201606 1.015 100.088 1.080
201609 0.962 99.604 1.028
201612 1.174 99.380 1.258
201703 0.624 100.040 0.664
201706 1.276 100.285 1.355
201709 1.237 100.254 1.314
201712 1.225 100.213 1.301
201803 0.784 100.836 0.828
201806 1.474 101.435 1.547
201809 1.373 101.246 1.444
201812 1.331 100.906 1.404
201903 0.837 101.571 0.877
201906 1.145 102.044 1.195
201909 1.740 101.396 1.827
201912 1.259 101.063 1.326
202003 0.892 101.048 0.940
202006 1.523 100.743 1.609
202009 1.099 100.585 1.163
202012 1.306 100.241 1.387
202103 0.562 100.800 0.594
202106 1.566 101.352 1.645
202109 1.946 101.533 2.040
202112 1.472 101.776 1.540
202203 0.353 103.205 0.364
202206 1.435 104.783 1.458
202209 1.949 104.835 1.979
202212 1.674 104.666 1.703
202303 1.211 106.245 1.213
202306 1.232 106.576 1.231
202309 2.263 106.570 2.261
202312 0.851 106.461 0.851
202403 0.539 106.461 0.539

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novartis AG  (OTCPK:NVSEF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novartis AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (Novartis AG) Headlines

From GuruFocus

This Overlooked Danger Could Tank Big Pharma Stocks

By Margaret Moran 09-01-2022

Top 5 2nd Quarter Trades of TEALWOOD ASSET MANAGEMENT INC

By GuruFocus Research GuruFocus Editor 07-20-2022